• N/A
    Market Cap
  • -99.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
08/31/2021
Income Statement
Total Operating Revenue
1.6M
N/A
Cost of Revenue
1.4M
N/A
Gross Profit
184,258
N/A
Sales and Marketing Expense
64,667
N/A
Research and Development Expense
N/A
N/A
Depreciation and Amortization Expense
45,482
N/A
Total Operating Expenses
2.1M
N/A
Operating Profit
-1.9M
N/A
Interest Income
-55,435
N/A
Interest Expense
-7.4M
N/A
Interest Income and Expense and Net
-7.5M
N/A
Total Nonoperating Income and Expense
-6.2M
N/A
Income before Taxes
-1.9M
N/A
Income Taxes
0
N/A
Extraordinary Items
N/A
N/A
Net Income
-7.8M
N/A
Net Income from Continuing Operations Applicable to Common
-7.8M
N/A
Basic EPS and Net Income
-0.13
N/A
Diluted EPS and Net Income
-0.13
N/A
Basic Weighted Average Shares
58.3M
N/A
Diluted Weighted Average Shares
58.3M
N/A
Balance Sheet
Cash and Cash Equivalents
30,813
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
30,813
N/A
Total Current Assets
442,065
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
218,535
N/A
Total Long-Term Assets
218,535
N/A
Total Assets
11.3M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
2.7M
N/A
Total Current Liabilities
8.7M
N/A
Total Long-Term Debt
672,794
N/A
Total Long-Term Liabilities
1.2M
N/A
Total Liabilities
10.0M
N/A
Retained Earnings
-13.9M
N/A
Total Stockholders Equity
-2.2M
N/A
Total Shares Outstanding
84.9M
N/A
Cash Flow
Cash from Operating Activities
-1.5M
N/A
Capital Expenditures
9,511
N/A
Cash from Investing Activities
-7,311
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
1.5M
N/A
Financials Ratio
Gross Margin
11.51%
N/A
Operating Margin
-121.42%
N/A
Return on Assets
-114.68%
N/A
Return on Equity
429.59%
N/A
Revenue Growth
5,828.89%
N/A
Current Ratio
0.05
N/A
Cash Ratio
0.004
N/A
Debt-to-Equity Ratio
-1.52
N/A
Debt-to-Assets Ratio
0.30
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow